Study guide

7.2 Acquired Coagulation Factor Deficiencies, Circulating Inhibitors & DIC

ASCP Hematology Technologist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Hematopoiesis & Cellular Physiology

1.1 Hematopoiesis, Bone Marrow Microenvironment & Growth Factors 1.2 Erythrocyte Physiology, Metabolism & Destruction Pathways 1.3 Leukocyte Kinetics, Morphology & Phagocytic Function 1.4 Platelet Physiology, Ultrastructure & Thrombopoiesis

2 Chapter 2: Erythrocyte Disorders & Non-Hemolytic Anemias

2.1 Iron Metabolism & Iron Deficiency Anemia 2.2 Anemia of Chronic Inflammation, Sideroblastic Anemias & Lead Toxicity 2.3 Hemoglobinopathies & Qualitative Globin Chain Defects 2.4 Alpha and Beta Thalassemias 2.5 Megaloblastic, Macrocytic & Hypoproliferative Anemias

3 Chapter 3: Hemolytic Anemias & Erythrocytosis

3.1 Intrinsic Hemolytic Anemias: Membrane & Metabolic Defects 3.2 Immune-Mediated Hemolytic Anemias & Paroxysmal Nocturnal Hemoglobinuria 3.3 Non-Immune Extrinsic Hemolytic Anemias & Microangiopathies 3.4 Polycythemia & Erythrocytosis Classification

4 Chapter 4: Benign Leukocyte Alterations, Acute Leukemias & Bone Marrow Evaluation

4.1 Quantitative Leukocyte Alterations, Toxic Change & Leukemoid Reaction 4.2 Inherited Leukocyte Anomalies, Reactive Lymphocytosis & Storage Disorders 4.3 Acute Myeloid Leukemia (AML) & Related Neoplasms 4.4 Acute Lymphoblastic Leukemia (ALL) & Precursor Lymphoid Neoplasms 4.5 Bone Marrow Examination, Differential & M:E Ratio Assessment

5 Chapter 5: Chronic Myeloid Neoplasms, MDS & Mature Lymphoid Neoplasms

5.1 Myelodysplastic Syndromes (MDS) & Overlap Syndromes 5.2 Chronic Myeloproliferative Neoplasms (CML, PV, ET, PMF) 5.3 Chronic Lymphocytic Leukemia & Indolent B-Cell Lymphomas 5.4 Aggressive Lymphomas, Hodgkin Lymphoma & Mature T-Cell Disorders 5.5 Plasma Cell Neoplasms & Monoclonal Gammopathies

6 Chapter 6: Hemostasis: Primary, Secondary & Fibrinolytic Systems

6.1 Primary Hemostasis, Platelet Receptors & Qualitative Platelet Disorders 6.2 Quantitative Platelet Disorders & Immune Thrombocytopenias 6.3 The Coagulation Cascade & Cell-Based Hemostatic Model 6.4 Fibrinolytic System, Natural Anticoagulants & Thrombophilia

7 Chapter 7: Factor Deficiencies, Coagulation Testing & Anticoagulation

7.1 Hereditary Coagulation Factor Deficiencies & von Willebrand Disease 7.2 Acquired Coagulation Factor Deficiencies, Circulating Inhibitors & DIC 7.3 Routine and Specialized Coagulation Testing & Mixing Study Interpretation 7.4 Anticoagulant Therapies, Laboratory Monitoring & Reversal Strategies 7.5 Viscoelastic Testing, Heparin Neutralization & Chromogenic Assays

8 Chapter 8: Hematology Laboratory Testing & Advanced Diagnostics

8.1 Automated Hematology Analyzers, Interference Flags & Manual Methods 8.2 Cytochemical Staining, Flow Cytometry & Molecular Diagnostics 8.3 Erythrocyte Sedimentation Rate, Hemolytic Indicators & Special Erythrocyte Studies 8.4 Cerebrospinal Fluid Analysis, Cell Counts & Cytology 8.5 Serous Effusions & Synovial Fluid Analysis

9 Chapter 9: Laboratory Operations, Quality Assessment & Safety

9.1 The Total Testing Process: Preanalytical, Analytical & Postanalytical Quality 9.2 Quality Control Statistics, Levey-Jennings Charts & Westgard Multirules 9.3 Laboratory Mathematics: Dilutions, Concentration, Molarity & Standard Curves 9.4 Method Evaluation, Diagnostic Statistics & Point-of-Care Testing 9.5 Regulatory Framework, Proficiency Testing & Competency Assessment 9.6 Laboratory Safety: Bloodborne Pathogens, Personal Protective Equipment & Chemical Hygiene 9.7 Emergency Response, Spill Management & Specimen Packaging and Transport 9.8 Hematology Instrumentation: Microscopy, Counters, Analyzers & Centrifuges

7.2 Acquired Coagulation Factor Deficiencies, Circulating Inhibitors & DIC

Key Takeaways Explain This Topic AI

Vitamin K deficiency and warfarin lower factors II, VII, IX, and X plus proteins C and S but leave factor V NORMAL; hepatocellular failure lowers factor V as well, so a factor V assay separates the two.

Factor VIII is synthesized by endothelium, so it is normal or increased in liver disease and DECREASED in disseminated intravascular coagulation, providing a second discriminator.

Acute DIC produces low platelets, prolonged PT and APTT, low fibrinogen, consumed antithrombin, schistocytes, and a markedly elevated D-dimer; D-dimer is specific because it reflects plasmin lysis of cross-linked fibrin only.

A specific factor VIII inhibitor is time and temperature dependent (worsens after 1-2 hours at 37 C) and is quantified in Bethesda units, whereas a lupus anticoagulant inhibits immediately, shows no incubation effect, and predisposes to thrombosis rather than bleeding.

Acquired von Willebrand syndrome arises with aortic stenosis, monoclonal gammopathy, and extreme thrombocytosis, and is recognized by loss of high-molecular-weight multimers with late-onset bleeding and no family history.

Last updated: August 2026

Acquired Coagulation Factor Deficiencies, Circulating Inhibitors & DIC

Acquired bleeding disorders are far more common at the bench than the hereditary hemophilias, and the ASCP BOC lists acquired factor deficiencies, inhibitors, and disseminated intravascular coagulation as separate disease-state topics. The recurring examination task is to read a PT/APTT/platelet/fibrinogen/D-dimer panel and decide whether the patient has failed production, accelerated consumption, dilution, or a circulating antibody.

1. Deficiencies of Production and Clearance

Unlike inherited single-factor deficiencies, acquired coagulopathies typically involve multiple factor abnormalities occurring secondary to underlying systemic diseases. [ ACQUIRED COAGULOPATHY DIFFERENTIAL ]

  • CRITERIA VITAMIN K DEFICIENCY SEVERE LIVER DISEASE
  • ─────────────────────────────────────────────────────────────────────────────────────────────────
  • Initial Prolonged Test PT prolongs first (FVII short t1/2) Both PT and aPTT prolonged
  • Factor VIII Activity STRICTLY NORMAL ELEVATED (Endothelial synthesis)
  • von Willebrand Factor (vWF) STRICTLY NORMAL ELEVATED (Endothelial synthesis)
  • Fibrinogen Level NORMAL Decreased / Dysfibrinogenemic
  • Platelet Count NORMAL Thrombocytopenia (Hypersplenism)
  • Reversal / Correction Parenteral Vitamin K1 4F-PCC / FFP / Liver transplant
  • 1. Vitamin K Deficiency

Biochemical Mechanism: Vitamin K is an essential fat-soluble cofactor required by hepatic microsomal γ \gamma γ -glutamyl carboxylase to convert specific glutamic acid (Glu) residues into γ \gamma γ -carboxyglutamic acid (Gla) on the amino-terminal domains of vitamin K-dependent procoagulant factors ( Factors II, VII, IX, and X ) and regulatory anticoagulant proteins ( Protein C, Protein S, and Protein Z ). Gla residues bind ionized calcium ( C a 2 + Ca^{2+} C a 2 + ), allowing these enzymes to anchor to negatively charged phosphatidylserine on activated platelets.

Consequence of Deficiency: In the absence of vitamin K, the liver secretes uncarboxylated, functionally inert molecules known as PIVKAs (Proteins Induced by Vitamin K Absence/Antagonism) , which cannot bind calcium or participate in clot assembly.

Coagulation Profile Dynamics:

Factor VII has the shortest biological half-life of all coagulation factors (~4 to 6 hours).

Consequently, in developing vitamin K deficiency, the Prothrombin Time (PT / INR) prolongs FIRST , while the aPTT remains normal.

As the deficiency progresses, Factor IX ( t 1 / 2 ≈ 24 hours t_{1/2} \approx 24\text{ hours} t 1/2 ​ ≈ 24 hours ), Factor X ( t 1 / 2 ≈ 36 hours t_{1/2} \approx 36\text{ hours} t 1/2 ​ ≈ 36 hours ), and Prothrombin/FII ( t 1 / 2 ≈ 60 hours t_{1/2} \approx 60\text{ hours} t 1/2 ​ ≈ 60 hours ) become depleted, causing subsequent prolongation of the aPTT .

Thrombin Time, Fibrinogen, Factor V, Factor VIII, and Platelet Count remain completely NORMAL.

Common Clinical Etiologies:

Prolonged broad-spectrum antibiotic administration (sterilizes intestinal microflora producing vitamin K 2 K_2 K 2 ​ / menaquinone).

Biliary tract obstruction, cholestatic jaundice, or fat malabsorption syndromes (celiac disease, Crohn's, cystic fibrosis).

Hemorrhagic Disease of the Newborn (Vitamin K Deficiency Bleeding / VKDB): Neonates possess low hepatic vitamin K stores, poor placental transfer, minimal vitamin K concentrations in human breast milk, and a sterile gut devoid of bacterial synthesis; routinely prevented by prophylactic intramuscular administration of Vitamin K 1 K_1 K 1 ​ at birth.

2. Coagulopathy of Severe Liver Disease

Pathophysiology: The liver parenchymal hepatocyte is the primary site of synthesis for nearly all procoagulant factors (Fibrinogen, Prothrombin, FV, FVII, FIX, FX, FXI, FXII, FXIII) and natural anticoagulants (Antithrombin, Protein C, Protein S).

The Crucial Laboratory Diagnostic Dichotomy:

Factor VIII and vWF are NOT synthesized by hepatocytes. They are produced and secreted by vascular endothelial cells (and sinusoidal endothelial/Kupffer cells).

In acute and chronic liver failure, cirrhosis, and viral hepatitis, circulating Factor VIII and vWF levels are NORMAL or MARKEDLY ELEVATED (often > 200 – 400 % >200\text{--}400\% > 200 – 400% of normal) as acute phase reactants and due to endothelial activation.

Distinguishing Liver Failure from Disseminated Intravascular Coagulation (DIC): Factor V and Factor VII are decreased in both conditions; however, Factor VIII is markedly elevated in uncomplicated liver disease , whereas Factor VIII is severely consumed and decreased in acute decompensated DIC .

Additional Laboratory Manifestations of Liver Disease:

Dysfibrinogenemia: Hepatocytes produce abnormal fibrinogen molecules with increased sialic acid content, impairing fibrin monomer polymerization (prolonged TT and Reptilase time).

Thrombocytopenia: Caused by splenic pooling/sequestration secondary to portal hypertension, coupled with reduced hepatic synthesis of thrombopoietin (TPO) .

  • 2. Dilutional and Consumptive Acquired Deficiencies
  • Disseminated Intravascular Coagulation (DIC): The Coagulation Profile

DIC is systemic, uncontrolled activation of coagulation triggered by tissue factor entering the circulation (sepsis, obstetric catastrophe, trauma, crush injury, burns, acute promyelocytic leukemia, snake envenomation, malignancy). Thrombin is generated faster than the natural anticoagulants can quench it, microthrombi consume platelets and factors, and secondary fibrinolysis then dissolves fibrin and releases fibrin degradation products. The result is simultaneous thrombosis and bleeding.

  • Laboratory Parameter Direction in Acute DIC Mechanism
  • Platelet count Decreased Consumed in microthrombi
  • PT and APTT Prolonged Consumption of factors V, VIII, and the common pathway

Fibrinogen Decreased (may be normal early, since it is an acute-phase reactant) Converted to fibrin and degraded by plasmin

  • D-dimer Markedly increased Plasmin lysis of CROSS-LINKED fibrin; the single most useful DIC marker
  • Fibrin degradation products (FDP) Increased Plasmin lysis of both fibrinogen and fibrin
  • Antithrombin activity Decreased Consumed neutralizing excess thrombin
  • Peripheral smear Schistocytes (usually under 10% of red cells) Mechanical fragmentation across fibrin strands
  • Thrombin time Prolonged Hypofibrinogenemia plus FDP interference with fibrin polymerization

Examination discriminators. D-dimer detects only cross-linked fibrin, so it is raised in DIC but NOT in primary fibrinolysis or in pure hypofibrinogenemia; the FDP assay cannot make that distinction because it also detects fibrinogenolysis products. In thrombotic thrombocytopenic purpura the platelet count is low and schistocytes are prominent, but PT, APTT, fibrinogen, and D-dimer are essentially NORMAL, because TTP is a platelet-VWF disease rather than a coagulation-factor disease. Chronic (compensated) DIC , typical of adenocarcinoma, may show a normal platelet count and normal screening times with an isolated raised D-dimer.

Liver Disease versus Vitamin K Deficiency: The Factor V Rule

Both prolong the PT first. Only the liver synthesizes factor V, and factor V is NOT vitamin K dependent.

Vitamin K deficiency or warfarin effect: factor VII decreased, factor V NORMAL , corrected by parenteral vitamin K.

Hepatocellular failure: factor VII decreased AND factor V DECREASED , not corrected by vitamin K. Factor VIII is normal or elevated in liver disease because it is made by endothelium, which further separates it from DIC, where factor VIII falls.

Dilutional Coagulopathy of Massive Transfusion

Replacement of more than one blood volume with crystalloid and stored red cells dilutes platelets and labile factors V and VIII. Hypothermia and acidosis independently impair enzyme kinetics and platelet function, and citrate load chelates ionized calcium. The laboratory picture is a prolonged PT and APTT with thrombocytopenia and hypofibrinogenemia but a normal or only mildly raised D-dimer, which separates it from consumptive DIC.

3. Circulating Inhibitors

An inhibitor is an immunoglobulin that neutralizes a coagulation factor or interferes with phospholipid-dependent assembly. The mixing study is the screening tool: an inhibitor fails to correct on a 1:1 mix with normal pooled plasma, whereas a factor deficiency corrects.

Inhibitor Target Mixing Study Behavior Confirmatory Assay Clinical Consequence

Alloantibody to factor VIII Factor VIII, in previously transfused severe hemophilia A Prolonged APTT that does not correct, and worsens after 1-2 h incubation at 37 C Bethesda assay (Nijmegen modification) Loss of response to factor concentrate; bypassing agents required

Acquired hemophilia A (autoantibody) Factor VIII, in a previously normal older adult, post-partum patient, or patient with autoimmune disease or malignancy Isolated prolonged APTT, time and temperature dependent, incomplete correction Bethesda assay; factor VIII activity markedly reduced Severe soft-tissue and mucosal bleeding with a NORMAL PT and normal platelet count

Lupus anticoagulant Phospholipid, not a specific factor Immediate non-correction with NO incubation dependence dRVVT and silica clotting time with confirm/screen ratio and phospholipid neutralization Associated with THROMBOSIS, not bleeding, despite the prolonged APTT

Acquired von Willebrand syndrome VWF, adsorbed or cleared in aortic stenosis, monoclonal gammopathy, myeloproliferative neoplasms with extreme thrombocytosis Variable VWF antigen, VWF activity, and multimer analysis showing loss of high-molecular-weight multimers Late-onset mucocutaneous bleeding with no family history

Amyloid-associated factor X deficiency Factor X, adsorbed onto amyloid fibrils Corrects (a true deficiency, not an antibody) Factor X activity assay Bleeding in systemic AL amyloidosis with prolonged PT and APTT

Time and temperature dependence is the classic examination cue. A factor VIII inhibitor is progressive: the immediate 1:1 mix may look nearly corrected, and only after 1 to 2 hours of incubation at 37 C does the APTT become clearly prolonged. A lupus anticoagulant inhibits immediately and shows no incubation effect. A Bethesda unit is defined as the amount of inhibitor that neutralizes 50% of factor VIII activity in normal plasma after 2 hours of incubation at 37 C; the Nijmegen modification buffers the normal pooled plasma with imidazole and uses factor VIII-deficient plasma as the diluent to improve specificity at low titers.